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Abstract: The clinical approach to thalassemia and hemoglobinopathies, specifically Sickle 
Cell Disease (SCD), based on transfusions, iron chelation and bone marrow transplantation 
has ameliorated their prognosis. Nevertheless, infections still may cause serious complications 
in these patients. The susceptibility to infections in thalassemia and SCD arises both from a 
large  spectrum  of  immunological  abnormalities  and  from  exposure  to  specific  infectious 
agents.  Four  fundamental  issues  will  be  focused  upon  as  central  causes  of  immune 
dysfunction: the diseases themselves; iron overload, transfusion therapy and the role of the 
spleen.  Thalassemia  and  SCD  differ  in  their  pathogenesis  and  clinical  course.  It  will  be 
outlined how these differences affect immune dysfunction, the risk of infec
of most frequent infections in each disease. Moreover, since transfusions are a fundamental 
tool for treating these patients, their safety is paramount in reducing the risks of infections. In 
recent years, careful surveillance worldwide
greatly transfusion transmitted infections, but the problem is not completely resolved. Finally, 
selected  topics  will  be  discussed  regarding  Parvovirus  B19  and  transfusion  transmitted 
infections  as  well  as  the  prevention  of  infectious  risk  postsplenectomy  or  in  presence  of 
functional asplenia.
Introduction:  Infections  are  a  frequent 
complication  of  thalassemias  and  hemo
globinopathies and they can be fatal. The morbility 
and mortality rate for infections vary throughout the 
world depending on differences in the epidemiology 
of each infection and on the socio
of  each  country  and  also  vary  depending  on  the 
preventive and therapeutic strategies adopted. In an 
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ach to thalassemia and hemoglobinopathies, specifically Sickle 
Cell Disease (SCD), based on transfusions, iron chelation and bone marrow transplantation 
has ameliorated their prognosis. Nevertheless, infections still may cause serious complications 
e patients. The susceptibility to infections in thalassemia and SCD arises both from a 
large  spectrum  of  immunological  abnormalities  and  from  exposure  to  specific  infectious 
agents.  Four  fundamental  issues  will  be  focused  upon  as  central  causes  of  immune 
ysfunction: the diseases themselves; iron overload, transfusion therapy and the role of the 
spleen.  Thalassemia  and  SCD  differ  in  their  pathogenesis  and  clinical  course.  It  will  be 
outlined how these differences affect immune dysfunction, the risk of infec
of most frequent infections in each disease. Moreover, since transfusions are a fundamental 
tool for treating these patients, their safety is paramount in reducing the risks of infections. In 
recent years, careful surveillance worldwide and improvements in laboratory tests reduced 
greatly transfusion transmitted infections, but the problem is not completely resolved. Finally, 
selected  topics  will  be  discussed  regarding  Parvovirus  B19  and  transfusion  transmitted 
prevention  of  infectious  risk  postsplenectomy  or  in  presence  of 
Infections  are  a  frequent 
complication  of  thalassemias  and  hemo-
globinopathies and they can be fatal. The morbility 
and mortality rate for infections vary throughout the 
world depending on differences in the epidemiology 
of each infection and on the socio-economic level 
of  each  country  and  also  vary  depending  on  the 
eventive and therapeutic strategies adopted. In an 
Italian  multicenter  study
1
second  cause  of  death  after  heart  failure  in 
thalassemia.  Similar  results  were  reported  in 
Greece
2 and in Taiwan
3, while in E
patients  in  Thailand,  infections  are  the  primary 
cause of morbidity and mortality
Considering  infections  in  sickle  cell  disease 
(SCD),  the  data  are  much  more  variable.  In  an 
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ach to thalassemia and hemoglobinopathies, specifically Sickle 
Cell Disease (SCD), based on transfusions, iron chelation and bone marrow transplantation 
has ameliorated their prognosis. Nevertheless, infections still may cause serious complications 
e patients. The susceptibility to infections in thalassemia and SCD arises both from a 
large  spectrum  of  immunological  abnormalities  and  from  exposure  to  specific  infectious 
agents.  Four  fundamental  issues  will  be  focused  upon  as  central  causes  of  immune 
ysfunction: the diseases themselves; iron overload, transfusion therapy and the role of the 
spleen.  Thalassemia  and  SCD  differ  in  their  pathogenesis  and  clinical  course.  It  will  be 
outlined how these differences affect immune dysfunction, the risk of infections and the types 
of most frequent infections in each disease. Moreover, since transfusions are a fundamental 
tool for treating these patients, their safety is paramount in reducing the risks of infections. In 
and improvements in laboratory tests reduced 
greatly transfusion transmitted infections, but the problem is not completely resolved. Finally, 
selected  topics  will  be  discussed  regarding  Parvovirus  B19  and  transfusion  transmitted 
prevention  of  infectious  risk  postsplenectomy  or  in  presence  of 
1,  infections  were  the 
second  cause  of  death  after  heart  failure  in 
thalassemia.  Similar  results  were  reported  in 
, while in E-beta thalassemia 
Thailand,  infections  are  the  primary 
use of morbidity and mortality
4. 
Considering  infections  in  sickle  cell  disease 
(SCD),  the  data  are  much  more  variable.  In  an Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
analysis  performed  on  306  autopsies  of  SCD 
patients between 1929 and 1996, infections are the 
most common cause of death in all age groups (33-
48%).  The  predominant  anatomic  site  involved 
(72.6%)  was  the  upper  respiratory  tract
5.  On the 
other hand, Darbari et al
6, in 141 autopsies in SCD 
patients    between  1976-2001,    reported  a  lower 
mortality  rate  due  to  infections  (18.4%) and 
infections  were  the  fourth  cause  of  death  after 
pulmonary  hypertension  (PHT),  the  and  renal 
failure.  Both  of  these  studies  were  conducted  in 
USA.  Perhaps  the  difference  between  these  two 
reports  reflects  an  improved  surveillance  of 
infectious  complications. Bacterial  infections  are 
the main cause of death in Angolese SCD patients 
(40.1%)
7. In France and England infections are the 
third  cause  of  death  and the  rate  is  much  lower 
(19%)
8. A cohort study on children affected by SCD 
shows that the therapeutic strategy currently in use 
(transfusions,  bone  marrow  transplantation, 
vaccinations and penicillin prophylaxis), decreased 
the  global  childhood  mortality,  in  particular  that 
which derived from infections, and it increased the
mean age at the time of death
9.
In this review we will compare and contrast the 
different  mechanisms  which  predispose  to 
infectious  complications  in  thalassemia  and  in 
hemoglobinopathies,  specifically  SCD.  We  will  
distinguish between those aspects deriving from the 
disease  itself  and  those  which  are  essentially 
therapy related. Thereafter, we  will examine  only 
selected issues from the large amount of data on the 
clinical management of infectious diseases, trying 
to determine if there are infections to which these 
patients are naturally susceptible and others that are 
primarily due to treatment. Finally, the last point on 
which we will focus is  how much some clinical 
aspects of these diseases (for example iron overload 
(IOL),    and  splenic  absence  (or  hypofunction) 
influence the outcome of certain infection such as 
Acquired  Immunodeficiency  Syndrome  (AIDS), 
hepatitis C virus (HCV)  or bacterial infections.
Etiology Of Risks Of Infections In Thalassemia 
And  Hemoglobinopathies:  The  susceptibility  to 
infections in thalassemia and SCD arises both from 
a  large  spectrum  of  immunological  abnormalities 
and from the exposure to infectious agents.
To  simplify  the  complex  scenario  of  immune 
system perturbations, four fundamental issues can 
be  addressed:  the  disease  itself,  i.e.  all  those 
changes inherent to the pathological process which 
can  interfere  with  the  immune  systems;  IOL, 
transfusion therapy and the role of the spleen.
Transfusion  and  chelation  therapies  represent 
true progress in the management of these diseases. 
In fact, they dramatically ameliorated the prognosis 
of  thalassemia  and  SCD,  as  epidemiological  data 
clearly  demonstrate
1,2,9.  Nevertheless,  the  benefits 
offered  by  allogenic  blood  transfusions  (ABTs) 
come together with the disadvantages of the high 
transfusion  burden  in  terms  of  direct  exposure  to 
infectious risks and, indirectly, transfusion related 
immunomodulation  (TRIM)  and  IOL.  Moreover, 
other  therapeutic  options  (splenectomy,  central 
venous catheters, bone marrow transplantation) or 
nutritional deficiency (zinc deficiency) contribute to 
the infectious risks.
Immunological  Abnormalities  In  Thalassemia 
And  SCD:  Recently,  the  immunological 
abnormalities observed in thalassemic patients were 
reviewed  and  listed  in  two  publications
10,11.  The 
immune alterations concern both the innate and the 
adaptive  immune  systems.  The  CD4/CD8 ratio  is 
lower  than  normal,  neutrophil  and  macrophage 
phagocytosis, neutrophil chemotaxis, natural killer 
(NK) function are  compromised;  C3 and C4 are 
reduced.    High immuglobulins  (Ig)  were  reported 
and  B  lymphocytes  were  found  to  be  increased, 
activated  with  impaired  differentiation.  Table  1
summarizes  the  most  important  evidence  in  the 
literature  (experimental  or  clinical),  indicating, 
where noted, the relationship between the immune 
alteration and the ABTs or the IOL. There are few 
inconsistencies among the various reports.
The role of the disease itself in inducing immune 
abnormalities  can  be  explained  by 
pathophysiological mechanisms of the disease, as is 
reported in the literature.
The  pathogenesis  of  thalassemia  is  based  on 
ineffective  erythropoiesis,  hemolysis,  and  a 
tendency to  increased iron absorption, inherent in 
the  disease  itself.  For  the  first  two  reasons,  the 
monocyte/macrophage  compartment  undergoes 
gross hyperplasia  and  is  hyperactive  in 
phagocytizing all defective erythroid precursors and 
erythrocytes
39,40,41.  This  increased  phagocytic 
activity  very  likely  reduces  the  capacity  of  the 
phagocytic  system  to  defend  against  pathogenic 
microorganisms.  For  the  same  reason,  the  pattern 
recognition  receptors  (PRR)  are  overwhelmed 
28.  
Moreover, in a study conducted in a mouse model 
of  β-thalassemia,  susceptibility  to  infection  by  L. 
Monocytogenes  and  of  S.  Typhimurium  was 
demonstrated  as  a  result  of  low  phagocytotic 
activity 
13. The authors suggest that, in this model, 
the relationship of this alteration to IOL not caused 
by transfusions but results from the disease itself. Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 1: MECHANISMS OF IMMUNE DYSFUNCTION IN THALASSEMIA. The most important immune dysfunctions reported 
in thalassemia are shown. Those  studies focusing on a specific pathogenic link between the immune alteration and iron overload 
(IOL) or allogenic blood transfusions (ABTs) are  indicated. The data are predominantly clinical. 
IMMUNE ABNORMALITY PATHOGENESIS REFERENCES
IMPAIRED MONOCYTE/MACROPHAGE 
ACTIVITY AGAINST PATHOGENS
Sternbach
12 1987
IOL Ampel
13 1989*
Pittis
14    1994
ABTs Sternbach
12 1987
IMPAIRED NEUTROPHIL FUNCTION
Matzner
15 1993
IOL
Bassaris
16 1982
Van Ashbeck
17  1984
Van Ashbeck
18 1984
Skoutelis
19 1984; 
Cantineaux
20 1987
ABTs Grady
21 1985
Sternbach
121987
DECREASED NK ACTIVITY
Dwyer
22 1987
Sen
23 1989
Ezer
24 2002
IOL Akbar
25 1986
IO   ABTs A    Akbar
25 1986
REDUCED ACTIVITY OF COMPLEMENT 
SYSTEM Sihnlah
26 1981
CYTOKINE DYSFUNCTION
Wanachiwanawin 
271999 
Ozinsky
28 2000
Ozturk
29 2001
ABTs Lombardi
30 1994
T  LYMPHOCYTE
DYSFUNCTION
REDUCED CD4
ELEVATED CD8
REDUCED CD4/CD8
Umiel 
311984;      Dwyer 
221987
Khalifa
32 1988;    Sen
23 1989
Dua
33 1993;          Ezer
24 2002, 
TaABT Kaplan 
341984;    Grady
35  1985
Pardalos
36 1987;  Hodge
37 1999
B  LYMPHOCYTE DYSFUNCTION
Umiel
31 1984;    Dwyer
22 1987
Sen
23 1989;        Speer
37 1990
Dua
33   1993;   
ABTs H    Hodge
36  1999
ELEVATED Ig PRODUCTION ABTs Akbar
38 1985
Dwyer
22 1987
*marks experimental or in vitro studies.
Finally, in clinical practice, it has been observed 
that  severe  anemia,  itself,  is  a  risk  factor  for 
bacterial  infections  in  thalassemia,  predominantly 
pneumonia
4 43. The current criteria for transfusion 
therapy  recommend  the  maintenance  of  Hb  level 
above  9  g/dl  but  in  some  countries  with  lower 
socio-economic levels, this optimal regimen is not 
assured.  In  these  cases,  anemia  itself  represents 
another risk factor for infections. 
As  far  as  SCD  disease  is  concerned,  its 
pathogenesis  is  quite  different  from  thalassemia. 
Ineffective  erythropoiesis  does  not  play  a  central 
role  as in  thalassemia. HbS polymerization  is  the 
trigger,  able  to  initiate  the  catastrophic  chain  of 
events  responsible  for  chronic  hemolytic  anemia 
and for vaso-occlusive (VOC) crises. The latter may 
cause organ damage in all parts of the body and it 
accounts  for  the  enormous  clinical  complexity  of 
this disease. Much evidence is consistent with the 
existence of a chronic inflammatory state in SCD, 
exacerbated  during  the  VOC  episodes
44,45 with 
participation  of  cells  (neutrophils,  macrophages Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
platelets), cytokines and adhesion molecules. Many 
signs of high oxidative stress  and decreased anti-
oxidant  defense are  present
46.  Moreover,  high 
interleukin-6  (IL-6)  levels  were  observed in 
SCD
47,48 in addition to interleukin-4 and interleukin-
10
48, 49. This cytokine elevation suppresses humoral 
and  cell-mediated  immune  function, increasing 
infectious  risks
49,50.  High values  of  soluble  IL-2 
receptors (sIL-2R), observed in a large number of 
SCD  patients,  were  interpreted  as  the  effect  of 
continuous IL-6 stimulation
51. 
Regarding  the  cellular  aspects  of  the  immune 
system, monocytes are continously activated, as is 
demonstrated by the upregulation and the atypical 
expression  of  CD1
52.  Neutrophil  dysfunction  was 
considered  a  very  important  functional  defect 
involved in  the  high  susceptibility to  infections
53. 
For example, neutrophils from SCD patients show 
high  expression  of  CD18,  a  molecule  correlated 
with adhesive properties, and they respond, in vitro, 
to  IL-8  with  enhanced  sensitivity
54.  This  feature 
renders  neutrophils  important  participants  in  the 
initiation of vaso-occlusion (VOCs)   but they are 
thus less available for defense tasks. 
In fact, VOC crises are responsible for  further 
immune abnormalities which are present to a lesser 
degree or absent in the steady state of the disease
55. 
For example, phagocytic activity rises during VOCs 
56.    Neutrophil  chemotaxis  is  normal  or  clearly 
reduced  in  the  steady  state  of  the  disease  but 
increases during VOC crises
57. This hyperactivity of 
the  monocyte/macrophage  and  neutrophil 
compartments  is  not  committed  to  defending 
against  pathogens  but  it  contributes  to  VOCs. 
Moreover, it is a source of oxidative stress which 
impairs the immune response (see below). 
As a further sign of inflammatory activation, the 
alternate  (pathway  of  complement  (AP50)  is 
reduced for consumption  in SCD patients and has a 
significant inverse correlation  with the number of 
crises,  while  circulating  immune  complexes  are 
elevated and they directly correlate with the number 
of complications of the disease
58. 
The last factor to consider is that in SCD, VOCs 
themselves can predispose, locally, to the onset of 
infectious  complications.  Respiratory  infections, 
frequently  following  the  acute  chest  syndromes 
(ACSs),  or  osteomyelitis  are  examples  of  this 
mechanism
59.
Another  difference  between  thalassemic  and 
SCD  patients  concerns  splenic  function:  SCD 
patients  undergo  functional  asplenia  due  to 
recurrent episodes of vaso-occlusion in this organ. 
Thus,  the  immunodeficiency  observed  in 
thalassemia  after  splenectomy  is often  naturally 
present even early in the life in SCD
60. This state 
particularly  favors  infections  by  encapsulated 
bacteria
61. 
Finally,  we  mention  that  some  immune 
alterations  similar  to  those  mentioned  for 
thalassemia  were  also  found  in  SCD:    CD4 
lymphocyte  reduction  and  CD4/CD8  ratio 
reduction
55,  62-64; natural killer lymphocyte reduced 
activity
64;  high  serum  immunoglobulin
65,  and 
elevated B lymphocytes
55. On the other hand, the 
published data are less uniform and there are also 
some  studies  reporting  the  normality  of  these 
immunological features
66,67.
Risks  Related  To  Iron  Overload:  Hereditary 
hemocromatosis  patients represent an ideal model 
to  understand  the  effects  of  IOL  on  immunity. 
Indeed,  many  studies  have  demonstrated  that 
immunological  function  is  largely  and  negatively 
influenced by iron excess
68. Many of the alterations 
observed  in  hereditary  hemochromatosis  were 
confirmed also in thalassemic patients (Table 1).
To  comment  on  the  numerous  data,  we  will 
outline only some specific aspects: for example the 
dual and opposing roles of the phagocytic system 
(monocyte/macrophages  and  neutrophils).  IOL 
damage derives from a disequilibrium between iron 
oxidation  (through  the  Fenton  reaction)  and  the 
effectiveness and availability of those systems able 
to counteract  oxidative  stress.    In  this  sense,  in 
addition to the antioxidant systems, ferritin and the 
monocyte/macrophage compartment also participate 
in clearing up toxic iron. Indeed, lysosomes in these 
cells  are  able  to  endocytose  both  free  iron  and 
ferritin and this contributes toward protection from 
iron
68 (Figure 1).  Additional  oxidative  stress  can 
destabilize  the  secondary  lysosomes  of  the 
macrophage,  and  their  protective  role  is  lost. 
Moreover,  phagocytosis  of  microorganisms,  of 
dyserythropoietic  precursors  and  of  senescent  or 
damaged  red  blood  cells  (intravascularly  and/or 
extravascularly)  causes  oxidative  stress 
69 which 
compounds  that  deriving  from  IOL.  Finally,  IOL 
impairs  phagocytosis
70 and  its  negative  effect  on 
neutrophil  function has  been  clearly 
demonstrated
70,71. Phagocytic function is the center 
of a vicious cycle, acting as a double edged sword: 
protective  against  oxidative  stress  while  also 
generating oxidative stress on the one hand, and on 
the other hand, having its own function impaired by 
the same oxidative stress (Figure 1). 
Finally,  the  scanty  detoxifying  properties  of 
lymphocyte  are  the  reason  for  their  numerous 
functional alterations related to IOL.Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 1. Risks related to iron overload.
In addition, regarding IOL, SCD seems to be a 
different  disease.  Indeed  non  transfused  SCD 
patients may present  with iron  deficiency (due  to 
intravavascular hemolysis)
72 and even in  transfused 
patients, the organ damage due to iron overload is 
less severe
73. Perhaps this difference derives from 
the significant contribution of inflammation to the 
pathogenesis  of  the  disease,  as  recent  studies 
evaluating  the  role  of  hepcidin  in  these  diseases 
have led us to hypothesize
74. A recent multicenter 
prospective study
75 seems to support the influence 
of ABTs and IOL on the prevalence of infections 
requiring hospitalization, and, in general, on the rate 
of  hospitalization,  in  SCD  patients.  Nevertheless, 
the  data  analysis  shows  a  very  complex  scenario 
and the results suggest that this topic needs further 
studies to be clarified. Indeed, the transfused SCD 
are  overall  adult  patients  with  more  severe  and 
advanced disease and, as the authors conclude, the 
differences observed may  be,  but  not  necessarily, 
attributable to ABTs and to IOL. 
We conclude by mentioning that in patients who 
underwent hematopoietic stem cell transplantation, 
IOL severity is related to high infectious risk and it 
negatively influences the outcome of infections in 
this patient group
76.
Risks  Related  To  Allogenic  Blood  Transfusions 
(ABTs): The data regarding transfusion transmitted 
infection (TTIs) risks in patients with thalassemia 
and  hemoglobinopathies  does  not  differ  from  the 
evidence in the literature regarding multitransfused 
patients  (MTPs)  in  general.  Hepatitis  C  virus 
(HCV),  Hepatitis  B  virus  (HBV),  Human 
Immunodeficiency virus (HIV) and Syphilis are the 
most  common  infection  agents  transmitted  via 
transfusions and routine screening is performed for 
these  agents  throughout  the  entire  world.  Other 
agents  are  routinely  screened  for,  in  different 
countries, according to epidemiologic alerts but also 
commensurate  with  economic  resources.  In  the 
USA,  for  example,  screening  for  Human  T-cell 
Lymphotropic  virus  (HTLV),  West  Nile  virus 
(WNV), Trypanosoma  cruzi and  Cytomegalovirus 
(CMV) is also routinely performed on blood units 
and screening is performed for bacteria in platelet 
units
77. Many other infectious agents are transfusion Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
transmissible.  The  data  in  the  literature 
demonstrated that some of these agents do not cause 
any clinical disease (GBV-C/HGV, SEN-V, TTV, 
HHV-8) while others represent a transfusional risk 
according to epidemiologic evidence. Thus, the risk 
of  these  agents  can vary  in  different parts  of  the 
world.  As  summarized  by  Vanvakas  et  al 
77
additional  infectious  agents  which  can  be 
transmitted by transfusion include: Parvovirus B19, 
Dengue  fever  virus  (DFV),  Babesia  microti, 
Plasmodia  species,  Leishmania,  Brucella and
Creutzfeldt-Jakob disease (vCJD) prions.
The  prevention  of  HBV,  HCV  and  HIV 
transfusion transmission represented a challenge for 
transfusion  medicine.  Two  weapons  play  a 
fundamental  role  in  the  war  against  these  viral 
agents.  The  primary  preventive  measure  is  the 
selection of appropriate eligibility criteria for blood 
donors;  the  second  line  of  prevention  includes 
testing  the  units  to  be  transfused  by  various 
laboratory methods. Both tools have been and are 
always in continuous evolution. Health surveillance 
throughout the world, including rapid information 
about disease epidemiology and travel patterns of 
people,  as  well  as  the  economic  and  political 
choices of each country and technological progress, 
have  all  contributed  in  the  past  and  continue 
contributing to assure transfusion safety. Since the 
discovery of HBsAg in 1963, diagnostic accuracy 
has  improved  progressively.  The  introduction  of 
Nuclear  Amplification  Tests  (NAT)  represented  a 
milestone.  A  suitable  example  is  transfusion 
transmitted  HCV  and  HIV.  Recently,  the 
centralized data of the American Red Cross blood 
donor  population  were  reviewed
78 and  the 
prevalence rates of disease marker positivity and the 
residual risk attributable to the window period were 
evaluated.  A  continuous  statistically  significant 
decrease  (p<0.001)  of  prevalence  rates  for 
infectious disease markers among first-time donors 
was observed in the period between 1995 and 2001. 
Examining the data, the effect of the introduction of 
NAT testing is clear: the estimated risk of collecting 
blood during the infectious window period for HCV 
was  1:276,000  and  1:1,935,000  respectively  with 
only  antibody  determination  compared  to  NAT, 
respectively.  Similarly,  the  risk  for  HIV  was 
1:1,468,000 and 1:2,135,000. The important role of 
the introduction of NAT is indirectly confirmed by 
the  evidence that a less impressive  reduction rate 
was  recorded  for  HBV  for  which  no  relevant 
diagnostic  improvements  were  achieved 
(1:205,000).  Furthermore,  another  interesting 
approach  to  TTI  evaluation  is  the  application  of 
mathematical models to calculate the residual risk 
of infection. The results obtained in the USA
79 for 
HCV, HBV and HIV, are similar to those reported 
by Dodd et al. In England
80 and in Canada
81 the 
residual risk is substantially lower, in comparison to 
the USA, for HCV (1: 30 million and 1:13 million 
respectively)  while  for  HIV  only  in  Canada  the 
residual risk is lower (1:7-8 million). Many clinical 
reports can be quoted to demonstrate the effect of 
the  more  advanced  diagnostic  tools  adopted  in 
transfusion  field.  For  example,  in  Italy,  a  recent 
epidemiologic  study  of  708  multitransfused 
children,  showed that HCV hepatitis,  transmitted 
by  transfusion,    disappeared  after  1992
82. 
Furthermore,  in  another  Italian  study,  performed 
retrospectively  from  1990  until  2007,  HCV-RNA 
negative  thalassemic  patients  were  significantly 
younger  than  positive  patients  (p<0.001)
83.  A 
survey of 399 patients with thalassemia and SCD  in 
Turkey
84 reported a prevalence of  0.75%, 4.5% and 
0 of positivity to HBsAg, HCV and HIV antibodies 
respectively  but  the  majority  of  this  positivity 
(77.7%) was found in patients transfused before the 
introduction of second generation testing. The most 
recent  data,  although  encouraging,  suggest  some 
considerations: different levels of blood safety are 
achieved  among  various  countries.  It  derives  that 
donor  screening  strategies  can  be  ameliorated. 
Finally the problem of HCV and also HBV (we will 
expand  on  this  below)  is  far  from  a  complete 
resolution. 
As  far  as  the  influence  of  ABTs  on  immune 
system is concerned, over 30 years ago, it was noted 
that patients who had received many ABTs prior to 
renal  transplantation  showed  a  better  rate  of 
allograft survival. This was the onset of a long and 
heated  debate  focused  on  understanding  the 
immunomodulation  induced  by  ABTs
85-87.  The 
debate  initially  began  from  the  data  of 
approximately  40  studies  which  indicated  that 
surgical patients receiving perioperative ABTs have
a higher risk of bacterial infections, demonstrating 
the  link  between  multiple  transfusions  and 
infectious risk. Recently, Vamvakas and Blajchman 
87 reviewed extensive evidence regarding this issue, 
summarizing the beneficial and deleterious effects 
of  ABTs.  TRIM  could  contribute  to  all 
immunological alterations listed above and it also 
reduces delayed-type hypersensitivy and it induces 
antiidiotypic  and  anticlonotypic  antibody 
production. A central role in pathogenesis of  TRIM 
is played by allogenic mononuclear cells, both for 
their presence and for the soluble substances they 
release  during  storage  of  blood  components. Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Moreover, the  soluble HL-A  class  I peptides that 
circulate free in allogenic plasma also contribute to 
the  generation  of  TRIM.  The  similarity  between 
donor  WBC  HLA  antigens  and  those  of  the 
recipient  is  able  to  induce  alloimmunization  (if 
HLA-DR  mismatch  is  high)  or  tolerance  and 
immunosuppression (if the mismatch is for only one 
HLA-DR  antigen).  For  these  reasons,  universal  
blood  unit  leukodepletion  in  the  prestorage  phase 
should be an important measure to prevent TRIM. 
Thalassemic patients represented an ideal setting to 
verify  the  usefulness  of  ABT  leukodepletion. 
Although  leukodepletion  reduces  non-hemolytic 
febrile  reactions  (NHFR)
88-90 and  anti-leukocyte 
antibodies and anti-platelet production
91,  92 it does 
not  modify  substantially  the  immunologic 
alterations  observed  in  thalassemic  patients 
92
Probably,  their  pathogenesis is  very  complex  and 
TRIM represents only one of the numerous factors 
interfering with immunity.
Risks  Related  To  Splenectomy  Or  Functional 
Asplenia: At the present time, as an effect of the 
hypertransfusion  regimen,  fewer  thalassemic 
patients  undergo  splenectomy
93.  However,  when 
transfusional  needs  rise  excessively,  splenic 
enlargement, or hypersplenism and/or compressive 
damage  occurs,  splenectomy  is  indicated.  We 
already  outlined  that  SCD  patients  often  present 
with functional asplenia early in life.
The spleen is very important for immunological 
surveillance.  It  is an  important  reservoir  of 
immunocompetent  lymphocytes
94.  In  asplenia  or 
functional  hyposplenia,  antibody  production  in 
response  to  new  antigens,  mediated  by  CD4 
function,  is impaired
95. Efficient  phagocytosis 
depends  on  splenic  macrophages  and  on  the 
production  of  many  substances  (opsonins, 
properdin,  tufsin)  which  are  reduced  in  asplenic 
organisms
96, 97. Chemotaxis  is also impaired 
98. For 
all  these  reasons,  when  the  spleen  is  absent  or 
poorly  functioning,  sepsis  can  occur  for  any 
pathogen agent. However, encapsulated pathogens 
(Streptococcus pneumoniae, Haemophilus influenza 
type B, Escherichia coli, Neisseria menigitidis) are 
the  most  fearsome.  Hansen  et  al
99 reviewed  the 
literature regarding overwhelming sepsis in subjects 
with surgical or functional asplenia. They compared 
the number of events of sepsis and fatal sepsis in 
recent reports to the same data obtained in 1973
100. 
In  1973,  sepsis  occurred  in  119  of  2796  cases 
(4.3%) and fatal sepsis occurred in 71 (2.5%). In the 
most recent series, sepsis occurred in 270 of 7872 
cases  (3.5%)  and  was  fatal  in  169  (2.1%)  The 
percent  reduction  of  sepsis  from  1973  to  most 
recent years was estimated -18 for sepsis and -16 
for fatal sepsis. In both series, thalassemia patients 
have  the  highest  frequency  of  sepsis  and  fatal 
sepsis.  No  comparison  was  possible  for  SCD 
because  data  before  1973  were  lacking.  The 
preventive strategy based on penicillin prophylaxis 
and vaccinations (see below) has been fundamental 
for this reduction of sepsis and fatal sepsis. 
Zinc deficiency: The link between zinc deficiency 
and  immunodeficiency  is  well  known 
101.  Some 
reports,  concerning  SCD  patients  focus  on  this 
aspect  and  the  beneficial  role  of  zinc 
supplementation
102,103.
Selected  Topics  Regarding  Clinical  Aspects  Of 
Infections  In Thalassemia  And 
Hemoglobinopathies:  The  amount  of  published 
data  on  the  clinical  aspects  of  infections  in 
thalassemia  and  hemoglobinopathies  is  enormous 
and it is difficult to summarize it. In part, they are 
recently reviewed by Vento et al
11. In the following 
section, we will focus on some specific aspects or 
new evidence arising from the literature, concluding 
by  emphasizing  the  importance  of  preventive 
measures in splenectomized patients.
Human Parvovirus B19: Human parvovirus (HPV) 
B19  is  a  small,  non  enveloped,  single  stranded 
DNA  virus  with  a  terminal  hairpin
104.  During 
replication,  two  proteins  (VP1  and  VP2)  are 
produced but also in the absence of replication it 
can  exert  its  toxic  effects.  After  infection,  a 
transient high titer viremia lasts one week; the HPV 
DNA  disappears  during  the  production  of 
neutralizing  antibodies  (IgM  for  6-8  weeks  and 
afterwards,  IgG).  This  protective  reaction  can  be 
absent in immunocompromised patients leading to 
the persistence of viral DNA. The clinical course is 
characterized by a flu-like syndrome (fever, chills, 
headache,  gastrointestinal  discomfort,  arthropathy 
and a typical slapped-cheek rash which, after two 
days also involves the arms and legs), sometimes 
complicated by a transient red cell aplasia (TRCA). 
In  fact,  HPV  B19  it  is  also  called  erythrovirus 
because it has a high and almost specific tropism for 
erythroid  progenitors  inducing  them  to  undergo 
apoptosis by the activation of the caspase pathway. 
In subjects with high erythroid turn over (such as 
those  with  congenital  red  cell  defects)  severe 
anemia with low reticulocyte counts may develop, 
requiring  transfusion  or  an  intensification  of  a 
previous  transfusion  regimen.  Moreover,  it  is 
presumed that the virus can stay in the bone marrow 
for  lifelong  duration,  although  this  point  is  not 
completely  clarified  and  there  is  evidence  that Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
persistently infected blood donors can transmit the 
infection through transfusions 
105, although the main 
route  of transmission  is  always  respiratory.  For 
these reasons the course of HPV B19 infection in 
thalassemia and hemo-globinopathies can be quite 
different from that in a healthy subject.
A  large  epidemiological  study of  633  children 
with  SCD  (older  than  12  months)  has  been 
reported
106.  They  were  examined  between 
November 1996 and December 2001. At the start of 
the  study,  187  children  (29.5%)  had  already 
contracted the disease (HPV B19 IgG+ and IgM-); 
their mean age was higher than that of serologically 
negative  subjects  (p<0.001)  and  fewer  underwent 
chronic  therapies  (regular  ransfusion  or 
hydroxyurea-HU).  The  second  cohort  of  patients 
(446;  70.4%)  included  those  completely  negative 
(IgG and IgM-) and those with a recent infection 
(IgG-,  IgM+).  The  follow  up  of  372  children 
belonging  to  this  group  revealed  important 
information: the rate of seroconversion; the features 
of seroconverted subjects, the prevalence of TRCA 
(severe  or  mild)  and  the  variables  related  to  the 
clinical course. 
One hundred-ten children (29.5%) seroconverted 
during the follow up (incidence rate 11.3 for 100 
patient-years;  95%  confidence  interval  [CI]  8.2-
14.4). It is very interesting that among them, fewer 
were  receiving  transfusions  (7  out  of  49;  14.3%; 
incidence rate 5.9 for 100 patients years, 95% CI 1-
15) than those treated with hydroxyurea (9 out of 
29; 31% ) or not transfused (global incidence rate 
for  non-transfused  and  HU  groups:  11.9  per  100 
patients years; 95% CI 7.6-16.2 p<0.06). Moreover, 
the only risk factor for seroconversion was having a 
sibling with a recent HPV B19 infection. These data 
can  be  important  for  what  we  will  discuss  later. 
SCD genotype, sex, age at the first serological test 
did not affect seroconversion.
Sixty-eight  TRCA  were  observed  during  the 
study: 3 in the HPV B19 IgG positive group (1.6%) 
and 65 in the other (59%). The univariate analysis 
showed  a  strong  association  between  acute  HPV 
B19  infections  with  fever  and  acute  splenic 
sequestration  (ASS),  while  the  multivariable 
analysis identified predisposing factors as ASS and 
painful episodes. Although the same evidence was 
not  clear  for  acute  chest  syndrome  (ACS), 
examining  all  children  admitted  with  fever  and 
pain, ACS was more common in those with HPV 
B19 infections. The only risk factor for TRCA was 
the  high  reticulocyte  count  before  the  infection. 
This study is rich in information and outlines many 
aspects  of  an  infectious  disease  which  has  some 
peculiarities in SCD as compared to other diseases 
with high erythropoietic turnover. Nevertheless, an 
important debate is taking place in the literature as 
to whether transfusions are an important source of 
HPV B19. This hypothesis arises from the detection 
of HPV B19 DNA in asymptomatic blood donors. 
In  the  previous  report
106,  treated  children 
(transfusion  or  HU)  seemed to  have  less 
seroconversion,  perhaps  because  a  lower 
proliferation  rate  of  the  erythroid  compartment. 
Other reports coming from the transfusion medicine 
field
107-109 support the evidence that transmission of 
HPV  B19  through  transfusion  always  plays  a 
secondary  role  compared  to  respiratory 
transmission.  As  a  result,  there  is  currently  no 
consensus  regarding  the  application  of  preventive 
measures to blood donors, blood units or to patients.
Yersinia  Enterocolitica:  The  well  known 
problematic  of  Yersinia  enterocolitica  sepsis  in 
thalassemia is another area in which some features 
of  the  disease  combined  with  the  side  effects  of 
therapy  increase  the  risk  of  infection.  In  fact 
Yersinia infection is favored by IOL either related 
to  the  disease  or  to  transfusions  and  it  can  be 
triggered by deferoxamine therapy 
110, 111
Transfusion Transmitted Infections (TTI)s: In a 
manner  analogous  to  the  risks  of  infectious 
diseases, the course and the outcome of the most 
common  TTIs  in  thalassemia  and 
hemoglobinopathies  are  influenced  by  the 
pathogenic  features  of  these  diseases  in  terms  of 
immunodysfunction and by IOL. 
HIV:  Human  Immunodeficiency  Virus  (HIV) 
disease  is  a  viral- related  progressive  immune 
depression  that  leads  to  depletion  of  CD4+ 
lymphocytes, and renders the individual at risk for 
many  types  of  opportunistic  infections
112.  As 
previously stated, a low CD4/CD8 ratio is one of 
the  most  frequent  abnormalities  in  patients  with 
thalassemias  and  hemoglobinopathies;  thus,  HIV 
disease is an example of negative interactions and 
bidirectional combination of the hematological with 
the  infectious  disease.  Similarly,  the  substantial 
degree of immunodysfunction related to IOL would 
influence the outcome of these diseases. However, 
there  are  all  too  few  studies  dealing  the  clinical 
aspects  of  HIV  infection  in  thalassemia  and 
hemoglobinopahies. 
Some years ago a large multicenter study was 
published
113 which  included  79  HIV  positive 
thalassemia patients from various countries (Brazil, 
Italy,  Greece,  Spain,  France,  United  Kingdom, Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Cyprus),  the  majority  of  whom  were  followed  in 
Italy (71%) and Cyprus (16%). The mean age was 
low enough (12 ± 6.6 years) to presume a prevalent 
transfusion  transmission  of  HIV  infection.  The 
progression to overt AIDS after seroconversion was 
estimated 1.4% after three years and 9% after five; 
no significant statistical association was found with 
age, sex, acute infection, or splenectomy. Two years 
later, the same investigator focused on the inverse 
relationship between the rate of progression of HIV 
and  the  dose  of  deferoxamine  used:  the  rate  of 
progression  decreases  as  the  mean  daily  dose  of 
drug  increases  (p<0.02)
114.  In  a  further 
publication
115 reporting the follow-up of the same 
patients,  a  multivariate  Cox  proportional  hazard 
analysis demonstrated a direct relationship between 
disease  progression  and  ferritin  values.  These 
studies, published at the beginning of the nineties,
included some patients treated with zidovudine. In 
subsequent  years  until  the  present  time,  a  large 
spectrum  of  therapeutic  options  are  available  for 
HIV infected patients: nucleoside analogues (NAs), 
non  nucleoside  reverse  transcriptase  inhibitors 
(NNRTIs),  protease  inhibitors  (PIs),  fusion 
inhibitors, CCR5 (receptor) inhibitors and integrase 
inhibitors
116,  which are  used also in  patients with 
thalassemia  and  hemoglobinopathies.  Finally,  we 
mention  that  the  effect  in  vitro  of  iron  chelators 
(deferoxamine, deferiprone,  deferasirox)  on  HIV 
replication  is  an  interesting  area  of  experimental 
research
117, 118.
HCV: Hepatitis C Virus still represents a fearsome 
disease, widespread worldwide: it is estimated that 
one hundred million people are infected throughout
the world 
119. It can have a mild presentation, not 
infrequently asymptomatic, in its acute phase and in 
a high percentage of cases, the initial infection goes 
unnoticed. However, the evolution rate to chronic 
disease of HCV hepatitis is high (at least 80% of 
acute cases) and the further evolution towards end-
stage  liver  disease,  cirrhosis,  and  hepatocellular 
carcinoma (HCC) are not infrequent
120.
The influence of IOL on the outcome of HCV 
infection  was  the  subject  of  debate  both  in 
nonthalassemic
121,122 and thalassemic patients.
Di Marco et al
83 reported that, in thalassemics, 
the  severity  of  liver  damage  (i.e.  the  finding  of 
fibrosis and histologic signs of cirrhosis) is clearly 
related  to  persistent  HCV  infection  (HCV  RNA 
positivity), predominantly for genotypes 1 and 4. In 
the same study, the data on the influence of IOL on 
liver  damage  in  HCV  RNA  positive  patients, 
although less impressive, are  however suggestive. 
Many other authors focused their attention on the 
relationship between IOL and the outcome of HCV; 
although these studies may reflect some reporting 
bias,  the  results    consistently  demonstrate  the 
presence of this negative link
123-128. Much important 
evidence  was  obtained  in  patients  who  survived 
hemopoietic  stem  cell  transplantation:  serial  liver 
biopsies,  performed  to  evaluate  histology  and 
hepatic iron content, demonstrated that either HCV 
or  IOL  are  independent  risk  factors  for  the 
progression  of    liver  fibrosis  and  they  have  an 
additive effects
129.
Since the 1990's, the management of HCV has 
been  characterized  by  remarkable  improvements 
which initially began with the use of α-Interferon 2a 
(α-IFN). The first clinical results obtained with α-
IFN  were  encouraging
130,  131.  α-IFN  also  showed 
long  term  efficacy
128:  36.5  months  (range  25-49 
months).  Syriopoulou
132 reported  a  complete 
sustained response after 8 years of therapy in 45% 
of  thalassemic  patients.  In  the  first  of  these  two 
studies, upon multivariate analysis, the absence of 
cirrhosis, low iron content and infection with non 
1b C virus type were independently associated with 
a complete sustained response. In the second study, 
younger  patients,  who  were  not  splenectomized, 
with a shorter duration of the infection, were more 
likely to respond to therapy. α-IFN was used also in 
patients  after  bone  marrow  transplantation:  it  did 
not  adverse engraftment  and was demonstrated to 
be efficacious and safe
133.
Thereafter, treatment options were enriched by 
the  introduction  of    pegylated  IFN  (PegIFN)  and 
ribavirin.  There  is  currently  an  ongoing  debate 
regarding the use of a combination of α-IFN  (or 
Peg-IFN) plus ribavirin in the treatment of HCV in 
thalassemia.  This  option  could  be  considered  at 
least for patients infected by type 1b virus which 
results in a more severe disease and it is resistant to
α-IFN as a single agent.  On the other hand, it is 
well  known  that  ribavirin  is  able  to  induce 
hemolysis and so in thalassemic patients the drug 
could  increase  the  need  for  transfusions,  thus 
worsening  IOL.  Although  this  is  a  definite 
possibility, preliminary experiences
134-136 with  this 
combination  are  positive  in  terms  of  efficacy  on 
HCV  infection.  Inati  et  al
135 reported  a  complete 
sustained response in  62% of patients using  both 
drugs  in  comparison  to  30%  using  IFN 
monotherapy (p=0.19). The patients required more 
transfusions but no worsening of IOL was observed. 
After the discontinuation of antiviral therapy, blood 
consumption  returned to pre-therapy level. Other 
authors
134, 136 reported similar results.Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
The last point concerns SCD patients; Teixera et 
al
137, described the histopathologic features of SCD 
patients with or without HCV. This work has many 
limitations,  as  the  authors  state.  Nevertheless,  it 
gives interesting information: liver damage in SCD 
was present in subjects infected with HCV. In those 
not  infected,  the  liver  changes  were  mild  and, 
despite  IOL,  little  fibrosis  was  present.  These 
observations  are  consistent  with  those  made  by 
Harmatz et al 
138 and they imply that SCD differs 
from  thalassemia  in  terms  of  the  interaction 
between iron overload and HCV in SCD.
HBV:  The  strategies  adopted  in  transfusion 
medicine  as  far  as  the  widespread  use  of 
vaccination  against  HBV  has  reduced  the 
prevalence of this hepatitis among multitransfused 
patients.  Nevertheless,  HBV  hepatitis  is  still  a 
serious public health problem. The reasons for this 
phenomenon  are  related  to  several  factors.  The 
routes of infection can be different (transfusion as 
compared to sexual or perinatal); the patients can be  
overt (HBsAg+) or occult (HBsAg – or anti HBc+/ 
HBsAg-) carriers; and the virus can be reactivated 
in  the  setting  of  immunosuppression.  Finally,  the 
protection offered by vaccination is not absolute 
139. 
How  can  the  risks  be  managed?  All  transfused 
patients  (who  were  vaccinated)  or  those  with 
HBsAg+,  must  be  tested  annually  for  all  HBV 
markers. The appearance of anti HBc positivity is a 
very  important  event  which  mandates  careful 
clinical evaluation
HBV may present as an acute hepatitis with a 
wide  range  of  manifestations,  from  mild  disease, 
sometimes asymptomatic, to a severe one which, in 
some  instances,  can  evolve  to  fulminant  hepatic 
necrosis which is not uncommonly fatal 
140. Apart 
from the acute phase, between 2 to 10% of patients 
evolve to chronic liver disease, and thereafter, end-
stage  liver  disease,  cirrhosis  and  hepatocellular 
carcinoma  (HCC)
141.  The  first  line  treatment, 
available for chronic HBV disease, is α-IFN. This 
drug should be used for one year. During this period 
the  goal  of  therapy  should  be the  complete 
clearance of HBV
142,  143. Unfortunately, only 25%-
40% of patients are noted to have a good response 
and  the  use  of  other  antiviral  drugs  (adefovir, 
tenofovir, lamivudine, telbivudine, and entecavir) is 
often  necessary
142.  Unfortunately,  the  major 
drawback  of  such  therapies  is  that  they  are  not
“curative”,  i.e.  these  drugs  can  reduce  the  viral 
replication, but they do not achieve complete viral 
clearance.  Nonetheless,  treatment  is  considered 
effective when  liver fibrosis  does not  progress to
cirrhosis
144. 
  
Prevention  Of  Bacterial  Infections  In 
Splenectomized  Patients:  The  risk  of  invasive 
bacterial  infection  in  splenectomized  patients  is 
well known. The data collected by Bisharat et al
145
supports  this  concept.  They  reviewed  28  studies 
amounting to 6,942 well-documented patients, 209 
of  whom developed  invasive  infection  (3%).  The 
incidence of infection was highest among patients 
with  thalassemia  major  (8.2%),  and  sickle-cell 
anaemia (7.3%). Furthermore, the highest mortality 
rates  were  observed  among  patients  with 
thalassaemia major (5.1%), and sickle-cell anaemia 
(4.8%).  Both  incidence  and  mortality  were 
significantly  higher  in  children  than  in  adults. 
Streptococcus pneumoniae was responsible for the 
majority  of  the  infections  (66%),  with  a  55.3% 
mortality  rate.  It  is  followed  for  incidence  by  H. 
influenzae  type  b,  Escherichia  coli,  and  Neiserria 
meningitides
146.  Less  common  causative  bacteria 
are Staphylococci, Streptococci, Pseudomonas, and 
Salmonella  species
147.  The  highest  mortality  rates 
were  attributed  to  gram  negative  bacteria  (62%), 
and Neisseria meningiditis (58.8%).
Thus the  prevention and treatment  of bacterial 
infections in splenectomized thalassemia and SCD 
patients is a life-saving intervention. Adamkiewicz 
et  al
148,  reviewing  the  records  of  1,247  children 
born after 1983, reported a clear beneficial effect of 
pneumococcal conjugate vaccine in the reduction of 
the incidence of invasive pneumococcal disease.
Some issues are of particular interest for clinical 
practice:    the  optimal  timing  of  vaccine 
administration, the efficacy of various vaccination 
strategies,  the  duration  of  penicillin  prophylaxis, 
and the role of partial splenectomy. Splenectomized 
and  hyposplenic  patients  must  receive  routine 
vaccination,  including  both  live  attenuated  and 
killed  vaccines
149,  but  they  should  also  be 
immunized  against  Streptococcus  pneumoniae,  H. 
influenzae type b, and Neisseria meningitides
147,150. 
In  the  case  of  elective  splenectomy,  vaccinations 
should be completed at least 2 weeks prior to the 
date of surgery.  
However,  vaccination  does  not  completely 
protect  against  infection  with  encapsulated 
bacteria
151 and prophylactic antibiotics have a role 
as  well.  In  a  prospective  multicentre  randomized 
study  in  pediatric  SCD  patients  aged  <3yrs, 
penicillin  prophylaxis  reduced  the  incidence  of 
pneumococcal bacteremia  by 84%.   There  are  no 
prospective studies in different clinical settings, but Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
in  a  retrospective  observation
152,  the  incidence  of 
post-splenectomy  sepsis  (PSS)  infection  and 
mortality  were  reduced,  by  47%  and  88% 
respectively,  after  the  introduction  of  penicillin 
prophylaxis.  The  patients  had  undergone 
splenectomy  for  different  reasons,  but  the  most 
relevant characteristic of the series is that 70% of 
the patients were immunized (54% out of them only 
against  pnemococcus).  Consequently,  antibiotic 
prophylaxis  is  recommended  for  all  children  <5 
years of age, regardless of immunization status, for 
all asplenic children <5yrs, for a duration of at least 
for  2  years  following  splenectomy,  since  most 
series demonstrate that 50% of PSS occurs within 
this  period
153.  The  debate  about  the  duration  of 
prophylaxis  is  still  open  and  the  emergence  of 
penicillin-resistant  pneumococci  indicate  that 
alternate therapy may be warranted.
Notwithstanding  the  risk  of  overtreatment,  the 
potential  catastrophic  clinical  course  of  bacterial 
sepsis in the splenectomized individual induces the 
physicians  to  start  antibiotics  at  the  first  sign  of 
infection. Patients should carry a medical alert card 
to  improve  the  speed  and  appropriateness  of 
treatment of postsplenectomy sepsis.
Subtotal  splenectomy  may  reduce  the  risk  of 
postsplenectomy  sepsis
154.  Nevertheless,  there  are 
not, at the moment, specific recommendations for 
this  procedure  which  has  technical  drawbacks  in 
this population including regrowth of the spleen and 
the need for reoperation
155.
Thus,  also  after  a  subtotal  splenectomy,  the 
guidelines  mentioned  above for  total  splenectomy 
should still be applied. 
Conclusions:  Thalassemia  and  SCD  each  have  a 
different  pathogenesis  and  this  implies  some 
differences  in  the  risks  factors  for  infectious 
complications.  The  strong  inflammatory  imprint 
and the frequent functional asplenia early in life in 
SCD are the most important, although not the only, 
differences between the two conditions. Moreover, 
although  transfusions  and  bone  marrow 
transplantation are important modalities to treat or 
cure both diseases, the additional problems arising 
from these procedures or from their adverse effects 
(for example IOL), have different implications. The 
knowledge  of  these  differences  is  essential  to 
efficiently  target  future  research  in  experimental 
and  clinical  fields  and  also  to  define  the  best 
practical  approach  in  the  prevention  and  in  the 
treatment  of  infectious  diseases  in  these  complex 
patients. 
Although  much  progress  has  been  made, 
infectious diseases still represent a major challenge
in  the  efforts  for  assuring  these  patients  enjoy  a 
good  quality  of  life  and  prolonged  survival.  The 
complexity  of  infectious  complications,  involving 
different  regions  of  the  body  demonstrates  that 
satisfactory  cooperation  among  specialists  in 
various  disciplines  (hematology,  microbiology, 
immunology, hepatology), both in experimental and 
in  clinical  fields,  is  fundamental.  Moreover,  as  a 
consequence of routine use of transfusions in these 
patients, transfusion medicine plays a central role. 
Ultimately,  infectious  diseases  in  thalassemia  and 
hemoglobinopathies represent an example for which 
global surveillance, involving countries throughout 
the  world,  coupled  with  an  open  exchange  of 
information  are  essential  for  achieving  a  high 
standard of patient care.
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